Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam

Journal of Applied Toxicology

Volumn 28, Issue 7, 2008, Pages 829-838

  Harirforoosh, Sam ^a,b   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Inflammation; Kidney; Meloxicam; Pharmacokinetics; Rat; Rofecoxib

Indexed keywords

CREATININE; CYCLOOXYGENASE 2; ELECTROLYTE; MELOXICAM; MOBICOX; NITRITE; NITROGEN; PLACEBO; POTASSIUM; ROFECOXIB; SODIUM; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHRONIC ARTHRITIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; ELECTROLYTE EXCRETION; INFLAMMATION; KIDNEY FUNCTION; MALE; NONHUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SINGLE DRUG DOSE; SODIUM URINE LEVEL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; KIDNEY; KIDNEY FUNCTION TESTS; LACTONES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; THIAZINES; THIAZOLES;

RATTUS;

EID: 54949095458     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1342     Document Type: Article

References (45)

1. Aghazadeh-Habashi A, Jamali F. Pharmacokinetic study of meloxicam in the rat. In Proceedings of the Canadian Society for Pharmaceutical Sciences 6th Annual Symposium; pp. 53-54.
2. Arend WP, Dayer JM. 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33: 305-315.
3. Boers M, Dijkmans BA, Breedveld FC, Camps JA, Chang PC, Van BP, Pauwels EK, Cats A. 1990. Subclinical renal dysfunction in rheumatoid arthritis. Arthritis Rheum. 33: 95-101.
4. Breyer MD, Harris RC. 2001. Cyclooxygenase 2 and the kidney. Curr. Opin. Nephrol. Hypertens. 10: 89-98.
5. Busch U, Heinzel G, Narjes H. 1995. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur. J. Clin. Pharmac. 48: 269-272.
6. Canadian Pharmacists Association. 2003. Compendium of Pharmaceutical and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa.
7. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald GA. 1999. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmac. Exp. Ther. 289: 735-741.
8. Chen YL, Le V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, De SM, Giroud JP, Flouvat B, Chauvelot-Moachon L. 1994. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin. Pharmac. Ther. 55: 649-660.
9. Davies NM, Skjodt NM. 1999. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin. Pharmacokinet. 36: 115-126.
10. Davies NM, Teng XW, Skjodt NM. 2003. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 42: 545-556.
11. Depre M, Ehrich E, Van HA, De L, I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ. 2000. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. J Clin. Pharmac. 56: 167-174.
12. de Vries HE, Blom-Roosemalen MC, van OM, de Boer AG, van Berkel TJ, Breimer DD, Kuiper J. 1996. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J. Neuroimmunol. 64: 37-43.
13. Didier N, Romero IA, Creminon C, Wijkhuisen A, Grassi J, Mabondzo A. 2003. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J. Neurochem. 86: 246-254.
14. DiJoseph JF, Walter TL, Hartman DA, Carlson RP. 1993. Kidney dysfunction in the arthritic rat. Int. J. Immunopharmac. 15: 933-941.
15. Emami J, Pasutto FM, Jamali F. 1998. Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. Pharm. Res. 15: 897-903.
16. Ferreri NR, An SJ, McGiff JC. 1999. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am. J. Physiol. 277: F360-F368.
17. Grisham MB, Johnson GG, Lancaster JR, Jr. 1996. Quantitation of nitrate and nitrite in extracellular fluids. Meth. Enzymol. 268: 237-246.
18. Guirguis MS, Sattari S, Jamali F. 2001. Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. J. Pharm. Pharm. Sci. 4: 1-6.
19. Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP. 2000. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab. Dispos. 28: 1244-1254.
20. Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP, Baillie TA. 2002. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab. Dispos. 30: 684-693.
21. Harirforoosh S, Jamali F. 2005. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2/COX-1 selectivity on urinary sodium and potassium excretion in the rat. Can. J. Physiol. Pharmac. 83: 85-90.
22. Harirforoosh S, Aghazadeh-Habashi A, Jamali F. 2006. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin. Exp. Pharmac. Physiol. 33: 917-924.
23. Jamali F, Sattari S. 2000. High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. J. Pharm. Pharm. Sci. 3: 312-317.
24. Julia V, Bueno L. 1997. Tachykininergic mediation of viscerosensitive responses to acute inflammation in rats: role of CGRP. Am. J. Physiol 272: G141-G146.
25. Kvien TK. 2004. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22: 1-12.
26. Laethem ME, Belpaire FM, Wijnant P, Rosseel MT, Bogaert MG. 1994. Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat. Chirality 6: 405-410.
27. Ling S, Jamali F. 2005. Effect of early phase adjuvant arthritis on hepatic CYP enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab. Dispos. 33: 579-586.
28. Mayo PR, Skeith K, Russell AS, Jamali F. 2000. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmac. 50: 605-613.
29. Monshouwer M, Witkamp RF, Nujmeijer SM, Van Amsterdam JG, van Miert AS. 1996. Suppression of cytochrome. Toxicol. Appl. Pharmac. 137: 237-244.
30. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. 1987. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J. Clin. Invest. 79: 1635-1641.
31. Ngure RM, Gateri LM, Ngotho JM, Ndung'u JM. 2000. Application of the Vettest 8008 system for the biochemical analysis of vervet monkey plasma. Vet. Rec. 146: 612-613.
32. Perrone RD, Madias NE, Levey AS. 1992. Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 38: 1933-1953.
33. Piafsky KM, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F. 1978. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. New Engl. J. Med. 299: 1435-1439.
34. Piquette-Miller M, Jamali F. 1995. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab. Dispos. 23: 240-245.
35. Roig F, Llinas MT, Lopez R, Salazar FJ. 2002. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 40: 721-728.
36. Ruderman EM. 2005. Current and future pharmaceutical therapy for rheumatoid arthritis. Curr. Pharm. Des. 11: 671-684.
37. Sattari S, Dryden WF, Eliot LA, Jamali F. 2003. Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. Br. J. Pharmac. 139: 945-954.
38. Schnellmann RG. 2001. Toxic responses of the kidney. In Casarett & Doull's Toxicology, Klaassen CD (ed.). McGraw-Hill: New York; 502.
39. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K. 2002. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin. Pharmac. Ther. 72: 50-61.
40. Sterczer A, Meyer HP, Boswijk HC, Rothuizen J. 1999. Evaluation of ammonia measurements in dogs with two analysers for use in veterinary practice. Vet. Rec. 144: 523-526.
41. Stichtenoth DO, Frolich JC. 2000. COX-2 and the kidneys. Curr. Pharm. Des. 6: 1737-1753.
42. Velpandian T, Jaiswal J, Bhardwaj RK, Gupta SK. 2000. Development and validation of a new high-performance liquid chromatographic estimation method of meloxicam in biological samples. J. Chromatogr. B Biomed. Sci. Applic. 738: 431-436.
43. Vio CP, Cespedes C, Gallardo P, Masferrer JL. 1997. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 30: 687-692.
44. Walker KA, Barber HE, Hawksworth GM. 1986. Mechanism responsible for altered propranolol disposition in adjuvant-induced arthritis in the rat. Drug Metab. Dispos. 14: 482-486.
45. Warner TD, Vojnovic I, Bishop-Bailey D, Mitchell JA. 2006. Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J. 20: 542-544.